Drugs moving into the clinic: 27
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| Orexo | OX 19 (sublingual desmopressin) | nocturia & urinary incontinence | New formulation of Ferring Pharmaceuticals' drug that mimics the action of antidiuretic hormone, also known as arginine vasopressin. It binds to V2 receptors in renal collecting ducts, increasing water resorption, and also stimulates release of factor VIII from endothelial cells due to stimulation of the V1a receptor. |
| TopoTarget & CuraGen | belinostat (PXD101) | Oncology - acute myeloid leukemia (AML) | histone deacetylase inhibitor (HDAC) |
| Roche & Memory Pharmaceuticals | R4996/MEM 63908 | Alzheimer's disease, schizophrenia, plus other psychiatric and neurological disorders. | partial agonist of the nicotinic alpha-7 receptor |
| Zydus Cadila Healthcare | ZYH7 | Metabolism - dyslipidemia | undisclosed |
| BioVascular & Revitus | BVI-007 | Cardiovascular - prevention of myocardial infarction, thrombotic stroke and death in patients who have had a previous cardiovascular event | Thrombopoeitin inhibitor |
